Biotech Venture Capital: An Even Better Escape Plan for Ph.D.’s and M.D.’s?

Talk to any advanced degree holders in biology/medicine, and you’ll hear a few complaints repeatedly:

“The pay is terrible! We grind away for peanuts in research.”

“It’s boring.”

“Why did I bother with this degree?”

For many, the solution seems obvious: Break into finance to earn more and do something more interesting.

There are plenty of options, such as healthcare investment banking, biotech hedge funds, and biotech equity research, but biotech venture capital seems to rank high on most lists.

What could be better than having entrepreneurs pitch you while you sit back and use your scientific knowledge to allocate millions of dollars?

It sounds like a dream, but only if your knowledge of “venture capital” stops there:

Why Biotech Venture Capital?

In theory, you’re interested in biotech venture capital so you can “make the world a better place” by funding life-saving therapies and cures for serious diseases and chronic medical conditions.

Oh, and unlike the tech bros with their AI, SaaS, drone, and crypto startups, you mean it because you fund products that literally save lives.

You have a special insight into the science due to your academic or medical background, and you have enough business experience to say whether the solutions are commercially viable.

Now moving back to “the reality zone,” the first point to understand is that biotech venture capital is much smaller than tech venture capital.

It’s roughly a 5 – 10x difference in total annual funding, depending on how you categorize companies.

Dealroom has a good breakout here:

If you group biotech and pharma companies, they represent ~20% of total VC funding.

The Financial Times presents slightly different numbers, focusing on just biotech, but the overall story is similar (it’s a small percentage of total annual funding).

Other differences include:

1. “Incubation” / Partnership Structure – Many of the top biotech VC firms incubate companies in areas like SF and Boston based on promising research; they use the research plus the promise of funding to act as co-founders and recruit teams to start the companies.
2. Crossover Strategies – Many biotech VC firms not only invest across all company stages (early, late, growth) but also in public equities because it’s possible for pre-revenue companies to go public in this industry.
3. Early-Stage vs. Late-Stage Split – Early-stage and late-stage investing always differ, but they’re arguably the most different in biotech because of the clinical trials and regulatory approval process required for drugs, therapies, and medical devices.
4. Recruiting – It is possible to break into biotech VC coming from investment banking or consulting, but plenty of Ph.D. and M.D. candidates and some biotech startup founders also get in.

As with most venture capital careers, you normally want to do biotech VC at the end of your career rather than the start.

It’s very difficult to pick winners due to the unpredictability of clinical trials, regulators, and the split between “payers” and “providers” in many markets, and most funds underperform the S&P 500 or outright lose money.

So, if you already have money from a previous career or successful startup exit, it’s fine.

But if you’re looking to build wealth, the most cynical joke about VC comes to mind:

“How do you make a small fortune in venture capital? Start with a large one.”

How Biotech VC Deals Differ from Tech VC Deals

I’ll start with my favorite chart, taken from the biotech hedge fund article:

Most biotech startups’ valuations remain close to their total capital raised until very late in the process.

So, it’s not unusual to see these types of patterns in VC funding rounds:

• Seed: $30M raised at a $5M pre-money valuation, so the VCs own ~86%
• Series A: $200M raised at a $100M pre-money valuation.
• Series B: $300M raised at a $1B pre-money valuation (more normal).

It would be strange for a tech startup to raise capital that exceeds its pre-money valuation – but it’s quite common in biotech.

Other deal differences include:

1) Capital Required – Biotech firms have traditionally required far more capital to develop and launch their products (hundreds of millions or billions). But this is changing a bit with the massive capital now required for AI and hardware-related startups.

2) Binary Outcomes and Bounded Valuations – The drug either works or it doesn’t. But it’s also less common to earn outsized returns because biotech valuation is less speculative, and investors tend to have a better idea of what they’re buying.

For example, everyone knows how many people have a certain disease, the percentage on treatments, and the typical pricing.

There will still be disagreements about points like the eventual market share, but valuation tends to be more “bounded” than with tech startups.

3) Downside Protection – It’s more common to see features such as participating preferred and liquidation preferences above 1x, especially in the late stages, because of the high risk of drugs failing the regulatory process.

 4) Value Inflection Points – These tend to happen at later dates because there are multiple rounds of clinical trials in most countries, and each stage could take years to complete.

 5) Science – Especially in the early stages, you need an excellent scientific background to understand these companies, including a broad knowledge of the most promising current research areas.

 6) Modeling and Valuation – We have an entire course on Biotech Valuation, but the short version is that you forecast revenue based on patient counts, pricing, and “peak sales,” and you probability-adjust all forecasts for the chances of regulatory approval. There may not be a Terminal Value in a biotech DCF because you normally assume that sales decline and fall to ~0 after “generics” (lower-cost competitors) enter the market.

The Top Biotech Venture Capital Firms

Even though biotech VC is niche, there are dozens of firms in the space (possibly hundreds, depending on the classifications).

So, I’ll divide this list by stage and strategy (early, late, growth, crossover, etc.):

Early-Stage VC Firms

These firms often act like “incubators,” finding promising research and then recruiting and funding teams to commercialize it:

Late-Stage, Growth, and Crossover VC Firms

These firms are more suited to the skills of financiers and consultants since the focus shifts to modeling revenue and cash flows:

Multistage VC Firms

These firms do everything from seed investing to public equities. Some do even more “exotic” deals, such as ones involving royalty/licensing arrangements with mature companies:

Diversified Firms with a Biotech Presence

Many of these larger/diversified firms are more interested in the broad “healthcare” space than biotech, but most have made at least a few biotech investments.

Recruiting for Biotech Venture Capital

To simplify, there are 3 main options for breaking into biotech VC: The science, finance, and startup paths.

I’ll recycle the chart from the venture capital careers article to illustrate:

1. Science: Do an M.D. or Ph.D., ideally in a high-profile area with published research at a top university, and then gain some finance or consulting experience and leverage that to break into a VC firm. You could work as a doctor or in R&D at a biopharma company after your degree, but it’s not strictly necessary. With this background, you’ll be a strong candidate for many early-stage VC firms that care mostly about your scientific prowess.
2. Finance: Work in a top healthcare investment banking or equity research group or do healthcare-related projects at a top consulting firm. Possibly join a biotech startup or do corporate development or corporate VC at a healthcare-related company, and then leverage this experience to target late-stage VC firms.
3. Startup: There is no real “path” for this one, but if you launch a biotech startup and successfully exit, you could potentially move into biotech VC directly from there. You will probably still need a scientific background to do this, though, so it’s more like a variant of the “Science” route.

You could complete a top MBA as part of this process, but it’s not necessary if you have top brand names and relevant experience.

The recruiting process itself consists of a ton of networking with VCs and VC-adjacent professionals via email, LinkedIn, and in-person events.

We’ve covered networking exhaustively on this site, so please see all the articles and reader stories about how to do it successfully.

One Final Note: An added wrinkle here is that the top biotech VC firms tend to be very “top-heavy,” meaning there aren’t many junior or mid-level roles available.

For example, Third Rock Ventures, as of the publication date, has only 5 professionals in the “Principals, Associates, and Fellows” category – but 20 Partners.

Many tech VC firms also have more MDs and Partners than junior-to-mid-level staff, but it’s even more extreme in biotech.

Interviews and Case Studies

Interviews depend on whether you’re interviewing for early-stage or late-stage/crossover roles and what your background looks like.

We have an article about venture capital interview questions, but I would summarize the main topics in biotech VC interviews as follows:

• Your Background: Expect the usual questions about your story, why VC, why this firm, your strengths and weaknesses, etc.
• Scientific Knowledge: Yes, this will come up in almost any interview, even if you don’t have a science background. Breadth of knowledge is also quite important; VCs want people who understand something about all the potential areas they could invest in, rather than just a single specialty.
• Market and Investment Questions: They’ll ask for your opinions on their current portfolio companies, the best markets to invest in within life sciences, how you would evaluate deals, and so on.
• Deal Experience: Particularly for late-stage firms, they’ll care about your experience with fundraising and M&A deals involving biotech companies. They could ask for work samples or explanations of what you did.
• Technical Questions: These are much more likely at late-stage firms. Expect the usual accounting, valuation, and VC funding questions about cap tables and different financing methods (e.g., convertible notes and SAFEs traditional priced equity).
• Case Studies and Modeling Tests: Formal case studies are unlikely at early-stage funds, but they could describe a company and ask for a verbal walkthrough of your decision-making process, how you’d approach the valuation, and the additional information you would need to make a yes/no investment decision. You’re more likely to get a modeling test, valuation, or cap table exercise at late-stage funds.

Biotech VC Careers, Salaries, and Exits

Many of the points about general VC careers also apply here: Expect the same progression up the ladder, similar on-the-job tasks, and similar lifestyle and hours (e.g., maybe 50 – 60 per week for Associates and 40 – 50 for senior roles).

Total compensation for Associates starts around the $150K – $250K level in the U.S., depending on the firm size and strategy, and progresses up to the $500K – $1M level, depending on performance and individual contributions.

John Gannon has the best VC compensation data and runs a survey to update it annually (but note that his numbers include only salary + bonus and not carry).

Some General Partners can potentially earn millions per year due to carried interest, but it takes a long time to reach that level, and it’s a highly political process.

The biggest downsides to biotech VC careers are:

1. Getting “Demoted” – Even if you have a Ph.D. or M.D., you’ll still enter VC as an entry-level Associate, which may feel like a demotion. The only exceptions are if you successfully exited a biotech startup or advanced to a high-level executive position in the industry.
2. Slow / Uncertain Progression – You might be used to a logical advancement process based on your performance, published papers, etc. But it doesn’t work like that in VC – sourcing an amazing deal will help your prospects, but it is highly political and doesn’t adhere to strict criteria.
3. Limited Exit Opportunities – Since the work is specialized, you don’t have that many exit options compared to fields like investment banking, private equity, or even equity research. You can always move to the corporate side, but biotech VC doesn’t set you up that well for private equity (for example) since the deals are so different.

Alternate Escape Plans: Biotech VC vs. Biotech ER vs. Healthcare IB

You might be reading this and thinking, “Wait, biotech VC sounds quite challenging to get into, and the rewards may not be that great.”

And… you’re correct!

It is extremely difficult to get into, there aren’t many junior-level spots, and the average person would probably earn more as a doctor once you factor in the stability it offers.

Just for fun, let’s consider the other “healthcare finance” options: Healthcare private equity, biotech hedge funds, healthcare investment banking, and biotech equity research.

You don’t have a real shot at hedge funds or private equity with only academic/medical experience, so it’s best to focus on banking and equity research as entry points.

Finance and business development roles at normal biopharma companies could also work, but they’re not quite as common as entry points into the industry.

Of these, equity research is probably more accessible if you’re older and have less of a business background.

Turnover is much higher in both IB and ER, there are more open positions than in biotech VC, and the pay is higher if you make it to the mid-levels or above.

However, the hours, lifestyle, and stress levels are also worse, and you will not have much of a life for a few years if you get into IB.

IB is also more difficult because recruiting is far more structured, and they often discriminate against older candidates, even if it’s technically illegal to do so.

Is Biotech Venture Capital a Good Genetic Match for You?

In my view, biotech venture capital is not the most realistic “escape plan” from academia or medicine, and it’s also not the best exit option for bankers and consultants.

For it to make sense, you need a very strong “angle”: Maybe you did research on the exact area of interest to a top firm, you launched a biotech startup or joined one early on, or you’re so fascinated by the industry that you want to stay in it for the long term.

With tech VC, by contrast, you could get in with the right background and “just enough” interest to appear credible.

And even if you end up not liking it, you could quit and move to a wider variety of other companies.

Biotech VC as an exit strategy has more strings attached, and you need to understand them all before playing with this tangled ball of yarn.